MA55899A - Polynucléotides codant pour la méthylmalonyl-coa mutase pour le traitement de l'acidémie méthylmalonique - Google Patents
Polynucléotides codant pour la méthylmalonyl-coa mutase pour le traitement de l'acidémie méthylmaloniqueInfo
- Publication number
- MA55899A MA55899A MA055899A MA55899A MA55899A MA 55899 A MA55899 A MA 55899A MA 055899 A MA055899 A MA 055899A MA 55899 A MA55899 A MA 55899A MA 55899 A MA55899 A MA 55899A
- Authority
- MA
- Morocco
- Prior art keywords
- methylmalonyl
- treatment
- coa mutase
- methylmalonic acidemia
- polynucleotides encoded
- Prior art date
Links
- 102000019010 Methylmalonyl-CoA Mutase Human genes 0.000 title 1
- 108010051862 Methylmalonyl-CoA mutase Proteins 0.000 title 1
- 201000003694 methylmalonic acidemia Diseases 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y504/00—Intramolecular transferases (5.4)
- C12Y504/99—Intramolecular transferases (5.4) transferring other groups (5.4.99)
- C12Y504/99002—Methylmalonyl-CoA mutase (5.4.99.2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845250P | 2019-05-08 | 2019-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55899A true MA55899A (fr) | 2022-03-16 |
Family
ID=71069931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055899A MA55899A (fr) | 2019-05-08 | 2020-05-08 | Polynucléotides codant pour la méthylmalonyl-coa mutase pour le traitement de l'acidémie méthylmalonique |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220370354A1 (fr) |
| EP (1) | EP3965806A1 (fr) |
| MA (1) | MA55899A (fr) |
| WO (1) | WO2020227615A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240269248A1 (en) * | 2021-05-19 | 2024-08-15 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
| WO2025235343A1 (fr) * | 2024-05-06 | 2025-11-13 | Huntsman Petrochemical Llc | Catalyseurs de polyuréthane stables |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| CA2563533C (fr) | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capables de faciliter la penetration a travers une barriere biologique |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| WO2006110776A2 (fr) | 2005-04-12 | 2006-10-19 | Nektar Therapeutics Al, Corporation | Compositions a base de polymere et conjugues d'agents antimicrobiens |
| US8309680B2 (en) | 2006-02-21 | 2012-11-13 | Nektar Therapeutics | Segmented degradable polymers and conjugates made therefrom |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| WO2011163483A2 (fr) | 2010-06-25 | 2011-12-29 | Massachusetts Institute Of Technology | Polymères pour des biomatériaux et des agents thérapeutiques |
| US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| CA2824526C (fr) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Lipides pegyles et leur utilisation pour une administration de medicament |
| WO2012109121A1 (fr) | 2011-02-07 | 2012-08-16 | Purdue Research Foundation | Nanoparticules glucidiques pour une efficacité prolongée d'un peptide antimicrobien |
| ES2795110T3 (es) | 2011-06-08 | 2020-11-20 | Translate Bio Inc | Lípidos escindibles |
| JP2014527071A (ja) | 2011-08-31 | 2014-10-09 | マリンクロッド エルエルシー | H−ホスホネートによるナノ粒子pegの改変 |
| WO2013086354A1 (fr) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipides biodégradables pour l'administration d'agents actifs |
| WO2013105101A1 (fr) | 2012-01-13 | 2013-07-18 | Department Of Biotechnology | Nanoparticules lipidiques solides encapsulant un médicament hydrophile/amphiphile et leur procédé de préparation |
| EP2804632B1 (fr) | 2012-01-19 | 2019-09-18 | The Johns Hopkins University | Nanoparticules présentant une pénétration mucosale améliorée |
| WO2013116126A1 (fr) | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Nouveaux lipides cationiques biodégradables de faible masse moléculaire pour la délivrance d'oligonucléotides |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| US20200131498A1 (en) * | 2017-06-14 | 2020-04-30 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| EP3849617A1 (fr) * | 2018-09-14 | 2021-07-21 | Translate Bio, Inc. | Compositions et méthodes de traitement de l'acidémie méthylmalonique |
-
2020
- 2020-05-08 MA MA055899A patent/MA55899A/fr unknown
- 2020-05-08 US US17/608,691 patent/US20220370354A1/en not_active Abandoned
- 2020-05-08 EP EP20731624.1A patent/EP3965806A1/fr not_active Withdrawn
- 2020-05-08 WO PCT/US2020/032055 patent/WO2020227615A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020227615A1 (fr) | 2020-11-12 |
| EP3965806A1 (fr) | 2022-03-16 |
| US20220370354A1 (en) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1063I2 (fr) | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih | |
| EP3490987A4 (fr) | Nouveaux agents thérapeutiques pour le traitement de l'infection par hbv. | |
| MA45052A (fr) | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille | |
| EP3893940A4 (fr) | Polythérapie pour le traitement de la dystrophie musculaire | |
| EP3600281A4 (fr) | Traitement d'association pour le traitement ou la prévention de tumeurs | |
| EP3570844A4 (fr) | Azolopyrimidine pour le traitement de troubles liés au cancer | |
| EP3458106A4 (fr) | Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie | |
| EP3642667C0 (fr) | Lentille de contact d'orthokératologie pour le traitement de la myopie | |
| EP3728271A4 (fr) | Composés macrocycliques pour le traitement de maladie | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| MA53609A (fr) | Polynucléotides codant la glucose-6-phosphatase pour le traitement de la glycogénose | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| EP3589307A4 (fr) | Régénération de neurones fonctionnels pour le traitement d'une lésion neuronale provoquée par une interruption de flux sanguin | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| EP3790867A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| MA54925A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| EP3445352A4 (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| EP3841086A4 (fr) | Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément | |
| EP3621635A4 (fr) | Virus enveloppé résistant à l'inactivation du complément pour le traitement du cancer | |
| MA50801A (fr) | Polynucléotides codant pour la phénylalanine hydroxylase pour le traitement de la phénylcétonurie | |
| EP3766497A4 (fr) | Médicament pour le traitement de la toux | |
| EP3612214A4 (fr) | Optimisation d'enzymothérapie de remplacement pour le traitement de l'homocystinurie | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| EP3898991A4 (fr) | Administration périnéale de résinifératoxine pour le traitement de la douleur maladaptative |